Last reviewed · How we verify

Icure Pharmaceutical Inc. — Portfolio Competitive Intelligence Brief

Icure Pharmaceutical Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
aricept Tab aricept Tab phase 3 Cholinesterase inhibitor Acetylcholinesterase Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Chung-Ang University Hosptial, Chung-Ang University College of Medicine · 1 shared drug class
  2. Eisai Co., Ltd. · 1 shared drug class
  3. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 shared drug class
  4. Merck Sharp & Dohme LLC · 1 shared drug class
  5. Novartis · 1 shared drug class
  6. Pfizer · 1 shared drug class
  7. Pontificia Universidade Catolica de Sao Paulo · 1 shared drug class
  8. Singapore General Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Icure Pharmaceutical Inc.:

Cite this brief

Drug Landscape (2026). Icure Pharmaceutical Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/icure-pharmaceutical-inc. Accessed 2026-06-10.

Related